

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

2023 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively the “**Group**”, “**We**” or “**Our**”) for financial year 2023 (the “**2023 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the “**IFRSs**”) (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 30, 2023

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* *For identification purpose only*

I. Important Notice

- 1.1 The Board, the Supervisory Committee and the Directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2023 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2023 Third Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 Ge Li, the person in charge of the Company, Ming Shi, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2023 Third Quarterly Report.
- 1.3 The 2023 Third Quarterly Report of the Company has not been audited.
- 1.4 Definitions

Definitions of frequently-used terms

“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“Board”	the board of Directors of the Company
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, excludes the Hong Kong Special Administrative Region of the PRC, the Macao Special Administrative Region of the PRC and Taiwan
“clinical trial(s)”	systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug
“CRDMO”	Contract Research Development and Manufacturing Organization
“CRO”	Contract Research Organization

“CTDMO”	Contract Testing Development and Manufacturing Organization
“Director(s)”	the director(s) of the Company or any one of them
“end of the Reporting Period”	September 30, 2023
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange
“IFRSs”	International Financial Reporting Standards issued by the International Accounting Standards Board
“IND filing”	filing for clinical trial of investigational new drug (IND), which is necessary before commencement of clinical trial
“Reporting Period”	the period from July 1, 2023 to September 30, 2023
“R&D”	research and development
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“SMO”	Site Management Organization
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisory Committee”	the supervisory committee of the Company
“U.S.”	the United States of America, its territories, its possession and all areas subject to its jurisdiction

II. Company Profile

As a global company with operations across Asia, Europe, and North America, the Company provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, the Company provides integrated, end-to-end services including chemistry drug CRDMO, biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

As at the end of the Reporting Period, the Company had 41,148 employees, including 12,877 employees with a master's or higher degree and 1,400 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

Position	Asia	U.S.	Europe	Total
Research and development	32,653	1,084	101	33,838
Manufacturing	3,771	219	71	4,061
Sales	59	116	32	207
Management and administration	<u>2,470</u>	<u>456</u>	<u>116</u>	<u>3,042</u>
Total	<u><u>38,953</u></u>	<u><u>1,875</u></u>	<u><u>320</u></u>	<u><u>41,148</u></u>

To maintain the high service standards and industry leading expertise and continuously meet customers' demands, the Company will continue to recruit, train, promote, incentivize and retain talented individuals.

III. Major financial data

1. Major financial statement items and financial indicators

Unit: RMB

Item	For the Reporting Period	Year-over-year increase/decrease (%)	From the beginning of the year to the end of the Reporting Period	Year-over-year increase/decrease (%)
			Period	
Revenue	10,670,040,635.96	0.30	29,541,326,133.58	4.04
Net profit attributable to the owners of the Company	2,763,287,456.82	0.77	8,076,407,160.91	9.47
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	2,948,329,613.55	23.76	7,709,412,169.46	23.70
Net cash flows from operating activities	Not applicable	Not applicable	10,316,787,859.57	33.82
Basic earnings per share (RMB/share)	0.94	1.08	2.75	9.13
Diluted earnings per share (RMB/share)	0.94	16.05	2.73	18.70
Weighted average return on net assets (%)	5.59	Decreased by 0.92 percentage points	16.19	Decreased by 1.53 percentage points
			Increase/decrease as at the end of the Reporting Period	
	As at the end of the Reporting Period	As at the end of the previous year	as compared to the end of the previous year (%)	
Total assets	71,759,281,237.93	64,690,326,746.96		10.93
Equity attributable to the owners of the Company	51,586,653,307.01	46,589,953,393.31		10.72

Note:

The “Reporting Period” hereinafter refers to the three-month period from the beginning to the end of the third quarter of 2023.

2. Non-recurring gain or loss items and amounts

Unit: RMB

Item	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets	48,711,664.58	42,351,833.54	
Government grants included in profit or loss of the current period, except for those closely related to the Company's normal operation and which were granted on a recurring basis subject to certain amount or volume upon fulfilment of specific standards in compliance with the government policies and regulations	60,534,356.50	286,542,935.38	
Gain or loss arising from changes in fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities, and other debt investments, except effective hedging business related to the Company's normal operations	-291,895,967.65	96,477,847.98	It was mainly due to changes in fair value and gains and losses on disposal of non-current financial assets and derivative financial instruments.
Other non-operating income and expenses other than the above items	-5,689,187.82	-20,236,671.94	
Less: Effect of income tax	-2,786,115.61	37,821,176.29	
Less: Impact on non-controlling interests (after tax)	-510,862.05	319,777.22	
Total	<u>-185,042,156.73</u>	<u>366,994,991.45</u>	

Explanation on classifying the non-recurring profit or loss items listed in the "Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Profit or Loss" as recurring profit or loss items

Applicable Not applicable

3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

✓ Applicable Not applicable

Item	Change (%)	Main reasons
Revenue for the period from the beginning of the year to the end of the Reporting Period	4.04	Please refer to the note below for details.
Net cash flows from operating activities for the period from the beginning of the year to the end of the Reporting Period	33.82	Mainly due to the steady growth in revenue collection and continued optimization of working capital management.

Analysis note:

Revenue

The Company provided services to customers in over 30 countries and regions through its 32 operating bases and subsidiaries worldwide. In the first three quarters of 2023, we added over 900 new customers, and in total we served more than 6,000 active customers over the past 12 months. Demand from customers across regions globally continued to grow. Revenue from US-based customers was RMB19.40 billion, excluding COVID-19 commercial projects, revenue grew 36% year-over-year; revenue from Europe-based customers grew 10% to RMB3.28 billion; revenue from China-based customers grew 5% to RMB5.24 billion; and revenue from other regions grew 10% to RMB1.62 billion. We have built a large and growing customer base with very strong customer stickiness. In the first three quarters of 2023, nearly 99% of total revenue was generated from existing customers, reaching RMB29.12 billion, which grew 26% year-over-year excluding COVID-19 commercial projects. At the same time, our new customers have provided us with broader opportunities to continuously follow new technologies and new modalities, in addition to their revenue contribution of RMB0.43 billion. We continued to execute our “long-tail” strategy and increase our support to large biopharmaceutical companies. Revenue from the top 20 global pharmaceutical companies maintained rapid growth and reached RMB11.82 billion in the first three quarters of 2023, which grew strongly by 43% year-over-year excluding COVID-19 commercial projects. Revenue generated from all other customers grew 16% year-over-year to RMB17.72 billion. Customers using services from multiple business units contributed RMB27.27 billion in revenue, growing by 28% year-over-year excluding COVID-19 commercial projects, accounting for an increased proportion of the Company’s revenue at 92%.

Unit: Million Currency: RMB

Operating Segments	First three	First three	Change	First three
	quarters of	quarters of		quarters
	2023	2022	(%)	of 2023
				Adjusted
				Non-IFRS
				Gross Profit
				Margin
				(%)
WuXi Chemistry	21,241.4	20,816.7	2.0	45.7
WuXi Testing	4,854.2	4,177.1	16.2	38.6
WuXi Biology	1,894.9	1,779.4	6.5	42.8
WuXi ATU	1,028.3	921.6	11.6	-6.1
WuXi DDSU	491.1	671.8	-26.9	31.6
Others	31.4	28.0	12.3	50.8
Total	<u>29,541.3</u>	<u>28,394.6</u>	<u>4.0</u>	<u>42.3</u>

Note: Any sum of the data above that is inconsistent with the total is due to rounding.

In the first three quarters of 2023, revenue of the Company was RMB29,541.3 million, representing a year-over-year (YoY) increase of 4.0% while revenue generated from principal business was RMB29,509.9 million, representing a YoY increase of 4.0% due primarily to the following:

(1) *WuXi Chemistry*

Revenue from WuXi Chemistry grew 2.0% year-over-year to RMB21.24 billion, excluding COVID-19 commercial projects, revenue grew strongly by 31.0%. Adjusted non-IFRS gross profit margin was 45.7%, with 4.5pts YoY improvement, mainly due to foreign exchange impact, while efficiency continued to improve. Drug discovery services (“**R**”) continued to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to customers, which grew 11% year-over-year. Through our “follow-the-customer” and “follow-the-molecule” strategies, we established trusted partnerships with our global customers, supporting the sustainable growth of our CRDMO business. We continued executing our “long-tail” strategy. Demand from “long-tail” customers in discovery services of small molecule and new modalities continued to grow, with the number of new customers growing 12% year-over-year. Development and manufacturing (D&M) services delivered strong growth. D&M services revenue grew 1.4% year-over-year to RMB15.63 billion in the first three quarters of 2023. Excluding COVID-19 commercial projects, D&M services revenue grew strongly by 48.2%. In the first three quarters of 2023, we added 926 molecules to our D&M pipeline. To date, our D&M pipeline has exceeded 3,000 molecules for the first time and reached 3,014, including 58 commercial projects, 61 in phase III, 316 in phase II and 2,579 in preclinical and phase I stages, among which, 12 commercial and phase III projects were added in the first three quarters of 2023. Specifically, TIDES business (mainly oligo and peptides) continued to expand. TIDES revenue grew strongly by 38.1% year-over-year to RMB2.07 billion in the first three quarters of 2023. Revenue in the fourth quarter of 2023 is expected to increase significantly, with TIDES full year 2023 revenue growth expected to exceed 60%. As of September 30, 2023, backlog of TIDES accelerated growth by 245% year-over-year. In the first three quarters of 2023, the number of TIDES D&M customers increased 31% year-over-year to 127, and the number of TIDES molecules increased 48% year-over-year to 230. We initiated capacity expansion in Changzhou and Taixing. The expanded workshops are expected to commence operation in December 2023, with the total reactor volume of peptide solid phase synthesizers increased from 20,000L to 32,000L.

(2) *WuXi Testing*

Revenue from WuXi Testing grew 16.2% year-over-year to RMB4.85 billion. Adjusted non-IFRS gross profit margin was 38.6%, with 1.8pts YoY improvement, mainly due to foreign exchange impact, while efficiency continued to improve. Revenue from lab testing services grew 16.3% year-over-year to RMB3.54 billion in the first three quarters of 2023. Among which, revenue from drug safety evaluation services grew 26.9% year-over-year. We maintained our industry leadership position in Asia Pacific for drug safety evaluation services that meet global regulatory requirements. Meanwhile, new facilities in Qidong and Suzhou have begun delivering new projects. Moreover, new modality capabilities continue to develop, while market share of nucleic acids, conjugates, and mRNA further expands, and new vaccine capabilities continue to improve. Revenue from clinical CRO & SMO grew 15.9% year-over-year to RMB1.32 billion in the first three quarters of 2023. SMO revenue grew strongly by 31.0% in the first three quarters of 2023, maintaining a leadership position in China. In the first three quarters of 2023, SMO supported 35 new drug approvals for customers. In the first three quarters of 2023, clinical CRO enabled our customers to obtain 13 IND approvals and submit 5 NDA filings.

(3) *WuXi Biology*

Revenue from WuXi Biology grew 6.5% year-over-year to RMB1.89 billion. Adjusted non-IFRS gross profit margin was 42.8%, with 1.6pts YoY improvement due to foreign exchange impact. The Company has one of the largest discovery biology enabling platforms, with approximately 3,000 experienced scientists (across 9 campuses in China, the U.S. and Germany), covering all stages of drug discovery and all major therapeutic areas. The Company focused on improving capabilities related to new modalities. The number of customers and projects served by our nucleic acid platform continued to increase. Cumulatively, we have provided services to over 130 customers, and have successfully delivered over 800 projects since 2021. In the first three quarters of 2023, WuXi Biology revenue from new modalities grew strongly by 35% year-over-year, contributing to 25.9% of WuXi Biology revenue. The comprehensive early discovery screening platform integrates multi-technologies (HTS, DEL, ASMS, FBDD, CADD etc.) and analysis capabilities of multi-dimensional databases, which can provide extensive and in-depth services to customers. In the third quarter of 2023, we launched the automated high-throughput protein production in Suzhou, and DELvision, a new service of chemical-proteome database to bridge the gap between small molecule chemical space and proteomics. Through accumulation of the eminent experimental data, DELvision empowers customers to effectively decipher the mechanism of protein-small molecule interactions. In the first three quarters of 2023, it continued to generate downstream opportunities and contributed more than 20% of the Company's new customers.

(4) *WuXi ATU*

Revenue from WuXi ATU grew 11.6% year-over-year to RMB1.03 billion. Adjusted non-IFRS gross profit margin was -6.1%, with 0.4pts YoY improvement due to foreign exchange impact. The Company focused on improving our CTDMO integrated enabling platform and strengthening capabilities and capacities. We provided development, testing and manufacturing services to 68 projects, including 7 Phase III projects (2 projects in BLA review stage, and 2 projects in BLA preparation stage), 9 Phase II projects and 52 preclinical and Phase I projects. In the first three quarters of 2023, we supported a customer to complete the BLA filing for a Tumor Infiltrating Lymphocyte (TIL) product with the FDA, which is expected to be the world's first innovative TIL-based therapy, and our facilities in Philadelphia (U.S.) successfully passed the FDA pre-license inspection (PLI). In addition, we supported a customer to file BLA for Lenti-viral Vector (LVV) used in a CAR-T product, and became the first CGT CDMO in China to pass Center for Food and Drug Inspection (CFDI) of National Medical Products Administration (NMPA) LVV on-site inspection. We expect that our customers will obtain approval for their products in the fourth quarter of 2023. Moreover, we completed the technology transfer for the manufacturing of a blockbuster commercial CAR-T product, whose process performance qualification is now in progress, and is expected to file pre-approval submission (PAS) to FDA in the first half of 2024. In June 2023, we signed a LVV manufacturing contract with a large pharmaceutical customer used in a commercial CAR-T product, which is expected to start manufacturing in the first half of 2024.

(5) *WuXi DDSU*

Revenue from WuXi DDSU declined 26.9% year-over-year to RMB0.49 billion. Adjusted non-IFRS gross profit margin was 31.6%, with 3.5pts YoY improvement mainly thanks to favorable project mix. In the first three quarters of 2023, 2 new drugs developed for our customers have obtained NMPA approvals, including one for COVID-19 infection treatment and the other for tumor treatment. Moreover, 2 new drug candidates are in the NDA review stage. We continued to receive the royalty income of the 2 approved new drugs from customers. Royalty income is estimated to grow with more than 50% CAGR over the next 10 years as more and more products are commercialized by customers. In the first three quarters of 2023, we supported customers to file INDs for 15 drug candidates and obtain 19 Clinical Trial Approvals (CTAs). Cumulatively, we have submitted 187 new chemical entity IND filings and obtained 163 CTAs for customers, among which 2 projects have obtained NDA approvals, 2 projects are in the NDA review stage, 5 projects are in Phase III, 29 projects are in Phase

II, and 70 projects are in Phase I, covering multiple therapeutic areas. Currently, we support 17 new modality projects covering Peptide/Peptide-Drug-Conjugation (PDC), protein degraders and oligo. Among which, 2 projects have entered clinical stage, while some projects have filed INDs, and multiple projects are expected to file IND in 2023.

In the fourth quarter of 2023, revenue will all come from non-COVID-19 commercial projects. Without COVID-19 commercial projects, we expect the Company's revenue in the fourth quarter to exceed RMB10 billion for the first time, among which WuXi Chemistry D&M will continue strong growth momentum and accelerate growth on top of the first three quarters. Excluding COVID-19 commercial projects, the Company's revenue in the fourth quarter is projected to grow 29-34%. Excluding COVID-19 commercial projects, revenue will grow 25-26% in 2023, with the Company's total revenue exceeding RMB40 billion for the first time. Due to lower than expected demand of early-stage drug discovery services, revenues from some lab service-related business will be significantly below budget. Therefore, we adjust 2023 YoY revenue growth from 5-7% to 2-3%; excluding COVID-19 commercial projects, revenue growth from 29-32% to 25-26%.

Due to foreign exchange impact and efficiency improvements, adjusted non-IFRS gross profit margin in 2023 expects to be up nearly 0.5pts and reaches 41.7-42.1%; with further improved operating efficiency, adjusted non-IFRS net profit attributable to the owners of the Company will exceed RMB 10 billion for the first time. Resulting from our unique CRDMO & CTDMO business model, better asset utilization and efficiency improvements, free cash flow under IFRS in 2023 expects to be up and reaches RMB 4.5-5.0 billion, which will be over 17 times as compared to last year.

The abovementioned operating performance forecast for the full year of 2023 is made based on the current order backlog of the Company. In addition, such operating performance forecast is subject to various prerequisites, including the stable development of the global pharmaceutical industry, the stability of the international trade environment and regulatory environment of the countries where the main operations of the Company are located. Further, such operating performance forecast does not constitute a profit forecast by the management of the Company for the full year of 2023 nor a substantive undertaking by the Company to investors. Its realization is subject to various factors including but not limited to changes in internal and external environment, where greater uncertainty exists.

IV. Information about shareholders

1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	202,845
Total number of preference shareholders with voting rights restored at the end of the Reporting Period (if any)	Nil

Shareholdings of top 10 Shareholders

Full name of shareholders	Nature of shareholders	Number of Shares held as at the end of the Reporting Period	Percentage (%)	Number of Shares subject to trading restrictions	Pledged, marked or frozen Shares Status	Number
HKSCC NOMINEES LIMITED ^(Note 1)	Overseas legal entity	402,500,362	13.5583	0	Unknown	0
Hong Kong Securities Clearing Company Limited ^(Note 2)	Overseas legal entity	264,445,691	8.9079	0	Nil	0
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	Overseas legal entity	159,160,073	5.3614	0	Nil	0
G&C VI Limited	Overseas legal entity	143,015,795	4.8175	0	Nil	0
G&C IV Hong Kong Limited	Overseas legal entity	104,626,051	3.5244	0	Nil	0
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業 (有限合夥))	Other	87,074,568	2.9331	0	Nil	0
G&C V Limited	Overseas legal entity	73,105,843	2.4626	0	Nil	0
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	Other	61,499,699	2.0716	0	Nil	0
China Life Insurance Company Limited — Traditional — General Insurance Products — 005L — CT001 Hu (中國人壽保險股份有限公司 — 傳統 — 普通保險產品 — 005L — CT001滬)	Other	54,817,084	1.8465	0	Nil	0
Bank of China Co., Ltd.-Hwabao CSI Medical Service Exchange-traded Open-end Index Securities Investment Fund (中國銀行股份有限公司 — 華寶中證醫療交易型開放式指數證券投資基金)	Other	43,514,263	1.4658	0	Nil	0

Shareholdings of top 10 holders of Shares not subject to trading restrictions

Full name of shareholder	Number of Shares not subject to trading restrictions	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED ^(Note 1)	402,500,362	Overseas-listed foreign shares	402,500,362
Hong Kong Securities Clearing Company Limited ^(Note 2)	264,445,691	RMB-denominated ordinary shares	264,445,691
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	159,160,073	RMB-denominated ordinary shares	159,160,073
G&C VI Limited	143,015,795	RMB-denominated ordinary shares	143,015,795
G&C IV Hong Kong Limited	104,626,051	RMB-denominated ordinary shares	104,626,051
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業 (有限合夥))	87,074,568	RMB-denominated ordinary shares	87,074,568
G&C V Limited	73,105,843	RMB-denominated ordinary shares	73,105,843
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	61,499,699	RMB-denominated ordinary shares	61,499,699
China Life Insurance Company Limited — Traditional — General Insurance Products — 005L — CT001 Hu (中國人壽保險股份有限公司 — 傳統 — 普通保險產品 — 005L — CT001滬)	54,817,084	RMB-denominated ordinary shares	54,817,084
Bank of China Co., Ltd. — Hwabao CSI Medical Service Exchange-traded Open-end Index Securities Investment Fund (中國銀行股份有限公司 — 華寶中證醫療交易型開放式指數證券投資基金)	43,514,263	RMB-denominated ordinary shares	43,514,263
Description of connected relationships or concerted actions of the above shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, and Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) being part of the top 10 shareholders of the Company, are acting in concert.		
The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any)	Not applicable		

Note 1: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

Note 2: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

V. Other reminders

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to.

Applicable Not applicable

VI. Quarterly financial statements

1. Type of auditor's opinion

Applicable Not applicable

2. Financial statements

Consolidated Balance Sheet

As at September 30, 2023

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	As at September 30, 2023	As at December 31, 2022
Current Assets:		
Bank balances and cash	9,448,561,845.32	7,985,741,393.85
Financial assets held for trading	3,210,072,026.91	2,000,000.00
Derivative financial assets	14,298,217.95	135,635,584.75
Note receivables	843,225.02	74,620,707.44
Trade receivables	7,605,627,345.21	5,972,777,810.06
Prepayments	264,018,875.09	290,612,821.22
Other receivables	69,373,421.65	169,309,944.71
Including: Interest receivables	—	—
Dividend receivables	—	—
Inventories	5,293,440,871.40	5,668,594,794.94
Contract assets	1,276,675,259.39	1,048,155,092.24
Non-current assets due within one year	1,674,979,863.08	1,427,794,911.22
Other current assets	919,298,660.64	1,221,983,479.78
Total Current Assets	29,777,189,611.66	23,997,226,540.21

Item	As at September 30, 2023	As at December 31, 2022
Non-current Assets:		
Long-term equity investments	1,162,875,678.36	1,202,930,849.89
Other non-current financial assets	8,887,883,288.16	8,954,329,860.71
Fixed assets	15,717,972,879.31	14,171,333,933.05
Construction in progress	7,612,767,738.53	7,473,305,409.62
Productive biological assets	1,126,996,000.00	937,985,000.00
Right-of-use assets	1,282,574,497.23	998,984,468.93
Intangible assets	1,910,683,093.47	1,784,832,359.55
Goodwill	1,872,069,798.24	1,822,101,781.03
Long-term deferred expenditures	1,691,012,787.63	1,810,854,549.30
Deferred tax assets	622,464,416.82	492,110,798.65
Other non-current assets	94,791,448.52	1,044,331,196.02
Total Non-current Assets	41,982,091,626.27	40,693,100,206.75
Total Assets	71,759,281,237.93	64,690,326,746.96
Current Liabilities:		
Short-term borrowings	4,631,117,062.62	3,874,119,856.00
Derivative financial liabilities	1,154,568,048.86	115,443,017.00
Note payables	—	18,620,505.45
Trade payables	2,201,394,873.03	1,640,693,871.65
Contract liabilities	2,297,181,339.21	2,496,636,589.50
Payroll payables	1,880,579,476.89	1,913,153,687.34
Tax payables	1,306,381,870.00	882,049,008.77
Other payables	3,307,164,521.77	3,331,218,622.01
Including: Interest payables	14,632,484.48	3,408,767.64
Dividend payables	—	—
Non-current liabilities due within one year	200,744,379.08	227,426,896.09
Total Current Liabilities	16,979,131,571.46	14,499,362,053.81

Item	As at September 30, 2023	As at December 31, 2022
Non-current Liabilities:		
Long-term borrowings	356,647,794.99	279,085,982.26
Bond payables	—	501,990,079.66
Including: Preference shares	—	—
Perpetual bonds	—	—
Lease liabilities	1,072,207,593.97	983,818,758.44
Deferred income	963,800,536.87	910,921,739.47
Deferred tax liabilities	399,091,348.31	440,461,919.35
Other non-current liabilities	—	148,013,478.22
Total Non-current Liabilities	2,791,747,274.14	3,264,291,957.40
Total Liabilities	19,770,878,845.60	17,763,654,011.21
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,968,655,855.00	2,960,526,697.00
Capital reserve	27,671,143,598.13	26,511,514,346.78
Less: Treasury shares	3,808,464,330.99	2,745,245,607.24
Other comprehensive income	-511,160,990.28	24,002,397.39
Special reserve	—	—
Surplus reserve	702,680,509.92	702,680,509.92
Undistributed profit	24,563,798,665.23	19,136,475,049.46
Total Equity (or Shareholders' Equity)		
attributable to owners of the Company	51,586,653,307.01	46,589,953,393.31
Non-controlling interests	401,749,085.32	336,719,342.44
Total Owners' Equity		
(or Shareholders' Equity)	51,988,402,392.33	46,926,672,735.75
Total Liabilities and Owners' Equity		
(or Shareholders' Equity)	71,759,281,237.93	64,690,326,746.96
Person in charge of the Company:	Ge Li	
Chief Financial Officer:	Ming Shi	
Director of the Accounting Department:	Jin Sun	

Consolidated Income Statement

January to September 2023

Prepared by: WuXi AppTec Co., Ltd

Unit: RMB Type of audit: Unaudited

Item	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
I. Total revenue	29,541,326,133.58	28,394,561,790.41
Including: Revenue	29,541,326,133.58	28,394,561,790.41
II. Total cost	20,390,754,912.94	21,159,921,597.90
Including: Cost	17,341,307,169.32	17,853,755,830.08
Taxes and surcharges	175,990,089.52	90,706,491.42
Selling expenses	521,220,394.83	555,299,587.48
Administrative expenses	1,979,875,643.41	2,040,026,783.97
Research and development expenses	1,025,811,070.87	1,089,268,152.01
Finance expenses	-653,449,455.01	-469,135,247.06
Including: Interest expense	113,947,206.59	70,546,311.05
Interest income	319,668,946.61	118,541,636.91
Add: Other income	286,536,806.88	224,609,998.02
Investment gains (“-” indicating loss)	463,436,866.04	420,983,118.79
Including: Gains from investments in associates and joint ventures	-51,583,124.74	-107,257,206.20
Gains from changes in fair value (“-” indicating loss)	102,676,079.72	1,095,201,959.52
Credit impairment losses (“-” indicating loss)	-128,620,014.23	-91,474,117.90
Assets impairment losses (“-” indicating loss)	-61,486,509.43	-34,482,484.73
Gains on assets disposal (“-” indicating loss)	-5,697,972.07	-7,282,339.87
III. Operating profit (“-” indicating loss)	9,807,416,477.55	8,842,196,326.34
Add: Non-operating income	6,624,331.87	6,239,512.33
Less: Non-operating expenses	32,074,532.76	29,166,086.82
IV. Total profit (“-” indicating total loss)	9,781,966,276.66	8,819,269,751.85
Less: Income tax expenses	1,633,319,192.33	1,372,652,145.65

Item	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
V. Net profit (“-” indicating net loss)	8,148,647,084.33	7,446,617,606.20
(I) Classified by continuity of operations		
1. Net profit from continuing operations (“-” indicating net loss)	8,148,647,084.33	7,446,617,606.20
2. Net profit from discontinued operations (“-” indicating net loss)	—	—
(II) Classified by ownership		
1. Net profit attributable to the owners of the Company (“-” indicating net loss)	8,076,407,160.91	7,377,913,928.98
2. Profit attributable to non-controlling shareholders (“-” indicating net loss)	72,239,923.42	68,703,677.22
VI. Other comprehensive income, net of tax	-543,935,758.12	-752,051,759.33
(I) Other comprehensive income attributable to owners of the Company, net of tax	-535,163,387.67	-740,124,849.48
1. Other comprehensive income that will not be reclassified to profit or loss	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-535,163,387.67	-740,124,849.48
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—
(2) Changes in fair value of other debt investments	—	—
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment allowance of other debt investments	—	—
(5) Cash flow hedging reserve	-967,296,336.10	-1,277,712,903.20
(6) Exchange difference on translation of foreign financial statements	432,132,948.43	537,588,053.72
(7) Others	—	—

Item	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
(II) Other comprehensive income attributable to non-controlling shareholders, net of tax	-8,772,370.45	-11,926,909.85
VII. Total comprehensive income	7,604,711,326.21	6,694,565,846.87
(I) Total comprehensive income attributable to owners of the Company	7,541,243,773.24	6,637,789,079.50
(II) Total comprehensive income attributable to non-controlling shareholders	63,467,552.97	56,776,767.37
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	2.75	2.52
(II) Diluted earnings per share (RMB per share)	2.73	2.30

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

Person in charge of the Company:	Ge Li
Chief Financial Officer:	Ming Shi
Director of the Accounting Department:	Jin Sun

Consolidated Statement of Cash Flows

January to September 2023

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
I. Cash flow from operating activities:		
Cash received from sale of goods or rendering of services	29,156,882,495.54	29,493,538,739.88
Refunds of taxes and surcharges	1,335,873,478.10	1,002,407,672.17
Cash received relating to other operating activities	1,070,091,927.36	398,595,973.58
Sub-total of cash inflow from operating activities	31,562,847,901.00	30,894,542,385.63
Cash paid for purchasing goods and receiving services	9,995,805,548.50	13,452,305,984.43
Cash paid to and on behalf of employees	8,258,283,939.09	7,177,292,652.12
Payments of taxes and surcharges	1,728,708,555.73	1,057,217,973.26
Cash paid relating to other operating activities	1,263,261,998.11	1,498,075,227.33
Sub-total of cash outflow from operating activities	21,246,060,041.43	23,184,891,837.14
Net cash flow generated from operating activities	10,316,787,859.57	7,709,650,548.49
II. Cash flow from investing activities:		
Cash received from disposal of investments	1,444,052,430.09	1,320,850,794.30
Cash received from return on investments	101,907,253.66	72,780,787.76
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	11,071,989.61	294,791,691.52
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	—	—
Sub-total of cash inflow from investing activities	1,557,031,673.36	1,688,423,273.58
Cash paid to acquire fixed assets, intangible assets and other long-term assets	3,649,714,542.52	6,746,412,720.88
Cash paid to acquire investments	3,667,190,618.13	1,035,634,022.34
Net cash paid to acquire subsidiaries and other business entities	22,091,789.01	—
Cash paid relating to other investing activities	—	21,193,032.64
Sub-total of cash outflow from investing activities	7,338,996,949.66	7,803,239,775.86
Net cash flow from investing activities	-5,781,965,276.30	-6,114,816,502.28

Item	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
III. Cash flow from financing activities:		
Cash received from capital contributions	58,303,918.84	63,670,747.14
Including: Cash received from capital contribution by non-controlling shareholders of subsidiaries	—	—
Cash received from borrowings	6,162,238,486.31	2,162,537,303.81
Cash received relating to other financing activities	—	—
Sub-total of cash inflow from financing activities	6,220,542,405.15	2,226,208,050.95
Cash repayments of borrowings	5,396,980,526.12	1,138,983,410.21
Cash payments for distribution of dividends, profits or interest expenses	2,733,548,830.21	1,572,965,368.08
Including: Dividends and profits paid by subsidiaries to non-controlling shareholders	—	—
Cash paid relating to other financing activities	1,394,000,468.50	213,568,167.72
Sub-total of cash outflow from financing activities	9,524,529,824.83	2,925,516,946.01
Net cash flow generated from financing activities	-3,303,987,419.68	-699,308,895.06
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	231,612,284.73	143,095,323.49
V. Net increase in cash and cash equivalents	1,462,447,448.32	1,038,620,474.64
Add: Balance of cash and cash equivalents at the beginning of the period	7,983,904,283.09	8,175,335,986.42
VI. Balance of cash and cash equivalents at the end of the period	9,446,351,731.41	9,213,956,461.06

Person in charge of the Company: Ge Li
Chief Financial Officer: Ming Shi
Director of the Accounting Department: Jin Sun

3. Adjustments on the financial statements at the beginning of the first year of adopting new standards since 2023

Applicable Not applicable

4. Quarterly condensed consolidated financial statements prepared in accordance with IFRSs

Consolidated Statement of Profit or Loss and Other Comprehensive Income
January to September 2023

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB'000		Type of audit: Unaudited	
	Third quarter of 2023 (July – September)	Third quarter of 2022 (July – September)	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
Revenue	10,670,041	10,638,304	29,541,326	28,394,562
Cost of services	<u>(6,154,250)</u>	<u>(6,600,180)</u>	<u>(17,469,850)</u>	<u>(17,929,613)</u>
Gross profit	<u>4,515,791</u>	<u>4,038,124</u>	<u>12,071,476</u>	<u>10,464,949</u>
Other income	182,861	113,264	622,662	353,813
Other gains and losses	14,896	668,443	1,076,049	2,058,328
Impairment losses under expected credit losses ("ECL") model, net of reversal	(31,078)	(35,209)	(132,778)	(93,959)
Impairment losses recognized on non-financial assets	—	—	(42,880)	—
Selling and marketing expenses	(167,746)	(199,686)	(521,220)	(555,300)
Administrative expenses	(732,540)	(791,339)	(2,059,022)	(2,099,150)
Research and development expenses	<u>(358,766)</u>	<u>(432,068)</u>	<u>(1,025,811)</u>	<u>(1,089,268)</u>
Operating profit	<u>3,423,418</u>	<u>3,361,529</u>	<u>9,988,476</u>	<u>9,039,413</u>
Share of results of associates	18,087	(35,977)	(58,387)	(106,812)
Share of results of joint ventures	(891)	(1,880)	6,804	(446)
Finance costs	<u>(53,861)</u>	<u>(45,264)</u>	<u>(154,927)</u>	<u>(112,885)</u>
Profit before tax	<u>3,386,753</u>	<u>3,278,408</u>	<u>9,781,966</u>	<u>8,819,270</u>
Income tax expense	<u>(595,002)</u>	<u>(507,449)</u>	<u>(1,633,319)</u>	<u>(1,372,652)</u>
Profit for the period	<u><u>2,791,751</u></u>	<u><u>2,770,959</u></u>	<u><u>8,148,647</u></u>	<u><u>7,446,618</u></u>

	Third quarter of 2023 (July – September)	Third quarter of 2022 (July – September)	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
Other comprehensive income (expense) for the period				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Exchange differences on translation of financial statements of foreign operations	55,435	253,703	432,402	536,288
Fair value losses on hedging instrument designated in cash flow hedges	(85,702)	(707,167)	(976,337)	(1,288,340)
Other comprehensive expense for the period, net of income tax	(30,267)	(453,464)	(543,935)	(752,052)
Total comprehensive income for the period	<u>2,761,484</u>	<u>2,317,495</u>	<u>7,604,712</u>	<u>6,694,566</u>
Profit for the period attributable to:				
Owners of the Company	2,763,287	2,742,165	8,076,407	7,377,914
Non-controlling interests	28,464	28,794	72,240	68,704
	<u>2,791,751</u>	<u>2,770,959</u>	<u>8,148,647</u>	<u>7,446,618</u>
Total comprehensive income for the period attributable to:				
Owners of the Company	2,734,277	2,295,330	7,541,244	6,637,789
Non-controlling interests	27,207	22,165	63,468	56,777
	<u>2,761,484</u>	<u>2,317,495</u>	<u>7,604,712</u>	<u>6,694,566</u>
Earnings per share (expressed in RMB per share)				
– Basic	0.94	0.93	2.75	2.52
– Diluted	0.94	0.81	2.73	2.30

Consolidated Statement of Financial Position

As at September 30, 2023

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	As at September 30, 2023	As at December 31, 2022
Non-current Assets		
Property, plant and equipment	25,014,616	23,444,883
Right of use assets	2,246,120	1,857,486
Goodwill	1,872,070	1,822,102
Other intangible assets	947,138	926,331
Interest in associates	1,087,686	1,135,669
Interest in joint ventures	75,190	67,262
Deferred tax assets	622,464	492,111
Financial assets at fair value through profit or loss (“FVTPL”)	8,887,883	8,954,330
Other non-current assets	101,929	1,054,942
Biological assets	1,126,996	937,985
	41,982,092	40,693,101
Current Assets		
Inventories	3,413,452	3,952,560
Contract costs	731,735	678,759
Biological assets	1,148,254	1,037,275
Amounts due from related parties	64,722	122,955
Trade and other receivables	8,794,439	7,590,361
Contract assets	1,276,675	1,048,155
Income tax recoverable	—	15,989
Financial assets at FVTPL	3,210,072	2,000
Derivative financial instruments	14,298	135,636
Other current assets	1,674,980	1,427,795
Pledged bank deposits	2,210	1,837
Bank balances and cash	9,446,352	7,983,904
	29,777,189	23,997,226
Total Current Assets	29,777,189	23,997,226
Total Assets	71,759,281	64,690,327

	As at September 30, 2023	As at December 31, 2022
Current Liabilities		
Trade and other payables	7,553,278	7,253,439
Amounts due to related parties	7,586	14,498
Derivative financial instruments	1,154,568	115,443
Contract liabilities	2,297,181	2,496,637
Borrowings	4,639,057	3,874,120
Lease liabilities	192,804	205,335
Income tax payables	1,134,657	517,797
Other current liabilities	—	22,092
	<hr/>	<hr/>
Total Current Liabilities	16,979,131	14,499,361
	<hr/>	<hr/>
Non-current Liabilities		
Borrowings	356,648	279,086
Deferred tax liabilities	399,091	440,462
Deferred income	963,801	910,922
Lease liabilities	1,072,208	983,819
Convertible bonds — debt component	—	501,990
Convertible bonds — derivative component	—	147,934
Other long-term liabilities	—	80
	<hr/>	<hr/>
Total Non-current Liabilities	2,791,748	3,264,293
	<hr/>	<hr/>
Total Liabilities	19,770,879	17,763,654
	<hr/> <hr/>	<hr/> <hr/>
Capital and Reserves		
Share capital	2,968,656	2,960,527
Reserves	48,617,997	43,629,426
	<hr/>	<hr/>
Equity attributable to owners of the Company	51,586,653	46,589,953
Non-controlling interests	401,749	336,720
	<hr/>	<hr/>
Total Equity	51,988,402	46,926,673
	<hr/> <hr/>	<hr/> <hr/>

Consolidated Statement of Cash Flows

January to September 2023

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
Net cash from operating activities	9,847,742	7,430,657
Investing activities		
Interests received	328,799	56,250
Proceeds from disposal of financial assets at FVTPL	1,446,531	1,337,325
Purchases of financial assets at FVTPL	(3,566,779)	(506,218)
Proceeds from disposal of property, plant and equipment and business	10,786	293,577
Proceeds from disposal of other intangible assets	286	1,214
Acquisition of interest in an associate	—	(529,416)
Purchases of property, plant and equipment	(3,530,768)	(6,624,337)
Payments for right-of-use assets	(118,933)	(118,988)
Purchases of other intangible assets	(14)	(3,087)
(Placement) withdraw of pledged bank deposits	(373)	63,137
Net cash outflow on acquisition of subsidiaries	(22,092)	—
Net cash outflow on deemed disposal of subsidiaries	—	(21,193)
Dividends received from associates	8,754	32,480
Dividends received from financial assets at FVTPL	28,122	23,826
Payments on derivative financial instruments	(100,411)	(1,897)
Payments for rental deposits	(3,846)	(10,894)
R&D grants and others received related to assets	203,173	161,504
Net cash used in investing activities	(5,316,765)	(5,846,717)

	First three quarters of 2023 (January– September)	First three quarters of 2022 (January– September)
Financing Activities		
Payments of dividends	(2,649,084)	(1,529,442)
New borrowings raised	6,162,239	2,162,537
Repayment of borrowings	(5,320,130)	(1,138,982)
Acquisition of partial interest of subsidiaries from non-controlling shareholders	(2,806)	(32,668)
Interests paid	(84,465)	(43,524)
Net proceeds from exercise of stock options	58,304	63,671
Payments on repurchase and cancellation of restricted A Shares	(425)	(3,367)
Repayments of lease liabilities	(205,138)	(166,640)
Repurchase of H shares	(1,181,786)	—
Redemption of convertible bonds	(76,850)	—
	<hr/>	<hr/>
Net cash used in financing activities	(3,300,141)	(688,415)
	<hr/>	<hr/>
Net increase in cash and cash equivalents	1,230,836	895,525
Cash and cash equivalents at the beginning of the period	7,983,904	8,175,336
Effects of exchange rate changes	231,612	143,095
	<hr/>	<hr/>
Cash and cash equivalents at the end of the period	<u>9,446,352</u>	<u>9,213,956</u>

5. Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company

Unit: RMB'000 Type of audit: Unaudited

	Third quarter of 2023 (July – September)	Third quarter of 2022 (July – September)	First three quarters of 2023 (January – September)	First three quarters of 2022 (January – September)
Net Profit attributable to the owners of the Company	2,763,287	2,742,165	8,076,407	7,377,914
Add:				
Share-based compensation expenses	156,206	143,410	480,588	503,413
Issuance expenses of Convertible Bonds	—	438	309	1,296
Fair value gain from derivative component of Convertible Bonds	—	(342,542)	(40,174)	(617,051)
Foreign exchange related gains	(18,289)	(207,418)	(354,782)	(365,948)
Amortization of acquired intangible assets from merge and acquisition	14,759	13,831	43,273	42,482
Impairment of non-financial assets	—	—	42,880	—
Non-IFRS net profit attributable to the owners of the Company	<u>2,915,963</u>	<u>2,349,884</u>	<u>8,248,501</u>	<u>6,942,105</u>
Add:				
Realized and unrealized losses (gains) from venture capital investments	155,590	119,705	(74,586)	(170,382)
Realized and unrealized share of losses (gains) from joint ventures	891	1,880	(6,804)	446
Adjusted non-IFRS net profit attributable to the owners of the Company	<u>3,072,444</u>	<u>2,471,469</u>	<u>8,167,111</u>	<u>6,772,168</u>

Note:

The discrepancies between the total and sums of amounts in the table above are due to rounding.